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Abstract: Pitavastatin was first developed in Japan and is expanding the regions in which it is 
clinically available. A considerable number of clinical studies have been conducted and published 
to date on the usefulness of pitavastatin for patients with primary hypercholesterolemia or com-
bined dyslipidemia. Pitavastatin demonstrates potent low-density lipoprotein cholesterol reduc-
tion at low doses of 1–4 mg/day. It also affects the regression of coronary plaques, as observed 
in intravascular ultrasound-guided percutaneous coronary intervention studies. Moreover, the 
persistent, long-term high-density lipoprotein cholesterol elevation observed in the populations 
treated with pitavastatin is worthy of further attention. The reported improvements in lipid 
profiles are consistent among the studies conducted in Japan, Korea, Thailand, and Europe. In 
light of accumulating clinical experience worldwide, pitavastatin is now expected to establish 
its position for preventing and treating cardiovascular disease.
Keywords: randomized clinical trial, Japan, Korea, Thailand, Europe
Introduction
Statins have contributed greatly to medical care since the late twentieth century 
through their role in the primary and secondary prevention of cardiovascular disease 
and reduction in total mortality. Compactin, the first statin, was discovered in the mid-
1970s by Akira Endo, who had been exploring a substance from fungi that inhibited 
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-determining 
enzyme in the cholesterol synthesis pathway.1 Thereafter, lovastatin, pravastatin, and 
simvastatin became clinically available in 1987, 1989, and 1992, respectively. More-
over, large-scale clinical studies, including the West of Scotland Coronary Prevention 
Study,2 the Air Force/Texas Coronary Atherosclerosis Prevention Study,3 Cholesterol 
and Recurrent Events,4 and Scandinavian Simvastatin Survival Study5 were success-
fully conducted, leading to the era of statin therapy. Thereafter, fluvastatin, cerivas-
tatin (withdrawn from the worldwide market in 2001), atorvastatin, pitavastatin, and 
rosuvastatin were developed.
Aggressive lowering of low-density lipoprotein cholesterol (LDL-C) levels is 
thought to be associated with a greater risk reduction for cardiovascular disease. Hence, 
aggressive lowering of LDL-C levels may benefit patients believed to be at risk for 
cardiovascular disease, even if their LDL-C levels are within the normal range for the 
general population, as well as patients with high LDL-C levels.6 Statins developed 
more recently exert more potent LDL-C reduction, allowing for more aggressive 
LDL-C-lowering therapy.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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The withdrawal of cerivastatin was due to reports that the 
risk for fatal rhabdomyolysis might be increased when it was 
used concomitantly with gemfibrozil.7 Since this incident, 
drug–drug interactions have attracted attention. Pitavastatin 
is the only statin (including its lactone form) that is scarcely 
metabolized by cytochrome P450 (CYP), a   drug-metabolizing 
enzyme in the liver.8 Hence, pitavastatin is thought to be 
minimally involved in drug–drug interactions mediated by 
CYP. This is an important property of pitavastatin because 
a lot of drug–drug interactions are recognized as a result of 
interferences in the metabolic pathway, the majority of which 
involve CYP isoenzymes. In fact, physicians should always 
take potential drug interactions into account with any drug 
to be administered, because multiple medications are often 
needed for patients with elevated cholesterol. As with other 
statins, other major causes of drug–drug interactions, ie, drug 
transporters, such as organic anion transporting polypeptide, 
also need to be carefully considered for pitavastatin.9
Pitavastatin was first developed and launched in Japan 
in 2003. Its safety and efficacy in Japan was established by 
the large-scale, prospective, post-marketing LIVES (LIValo 
Effectiveness and Safety) study, conducted in 20,000 patients 
with a two-year follow-up for each patient over six years 
since 2003.10 Pitavastatin’s usefulness has been reported in 
the results of many other clinical studies. To date, the find-
ings indicate that pitavastatin has not only a potent LDL-C-
lowering effect but also a long-term high-density lipoprotein 
cholesterol (HDL-C)-elevating effect.11 Pitavastatin became 
available in Korea in 2005, followed by approval in Thailand 
and China. It was recently approved by the Food and Drug 
Administration (FDA) in the US in August 2009. Pitavasta-
tin is also being reviewed in Europe, and is expected to be 
approved there in 2010. Therefore, pitavastatin’s usefulness is 
expected to be confirmed worldwide in the future. This paper 
reviews the clinical studies conducted and published to date 
on the usefulness of pitavastatin for patients with primary 
hypercholesterolemia and those with combined dyslipidemia, 
for which pitavastatin is indicated.
Methods
Articles for this review were selected to examine LDL-C 
reduction by dose, safety, and the long-term HDL-C-
elevating effect of pitavastatin in patients with primary 
hypercholesterolemia or combined dyslipidemia.
To examine LDL-C reduction and safety of pitavastatin 
at different doses, a systematic review was conducted on ran-
domized active-controlled studies that compared the effects 
of pitavastatin with those of other statins in patients with 
primary hypercholesterolemia or combined dyslipidemia. 
Relevant articles were searched for in PubMed on 26 April 
2010, using the search term “pitavastatin” and “randomized”. 
Thirty-seven papers11–47 were found. Four of these papers 
were reviews,11–14 two were articles on rationale and design 
of clinical studies,15,16 two were nonclinical studies,17,18 and 
five were pharmacokinetic studies,19–23 so were excluded. 
One interventional study of an unspecified statin,24 two clini-
cal studies using unspecified doses of pitavastatin,25,26 and 
three studies that did not report percent change in LDL-C 
with different doses of pivastatin27–29 were also excluded. In 
addition, one nonrandomized comparative study and seven 
studies that compared pitavastatin treatment with nonstatin 
treatment, lifestyle modification, or combined treatment with 
pitavastatin and other agents were further excluded,30–36 as 
were two studies conducted in patients with familial hyperc-
holesterolemia.37,38 However, one study conducted in patients 
who had glucose intolerance and baseline lipid levels similar 
to those in the other included articles39 and another two 
studies conducted in patients with acute coronary syndrome 
(ACS)40,41 were included. Moreover, two Phase III studies 
reported in Europe that were not found from the search 
results (one found in a review article and the other reported 
in a congress meeting were included).48,49 Thus, a total of 11 
articles39–47 were reviewed.
Five studies of the long-term treatment with pitava-
statin39,48–53 were reviewed. These papers were selected in a 
similar way to the abovementioned clinical studies, and all had 
study durations of more than 52 weeks or 12 months. Of those 
identified in PubMed using the keyword “pitavastatin”, review 
articles, commentaries, nonclinical and pharmacokinetic 
studies, and those focusing on rationale and/or study were 
excluded. Articles on HDL-C were also excluded if patients 
were treated with unspecified statins, data for HDL-C levels 
were not available for more than three visits, or the paper 
was a case report for one or two patients. A further study not 
identified on PubMed, but in which one of the authors of the 
present review participated, was included.50
LDL-C reduction and safety  
of pitavastatin
Randomized controlled studies that compared the effects 
of pitavastatin with those of other statins in patients with 
primary hypercholesterolemia or combined dyslipidemia, 
including some patients with glucose intolerance or ACS, 
were reviewed (Table 1). Relatively high percent reductions 
in LDL-C were reported, including 37.4% using 1 mg/day 
pitavastatin in Thailand,42 42.6% using 2 mg/day pitavastatin Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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trial, 251 hypercholesterolemic patients with TC levels 
$ 220 mg/dL and TG levels , 400 mg/dL were randomized 
to receive 2 mg/day pitavastatin or 10 mg/day atorvastatin. 
The primary endpoint was the percent change in non-
HDL-C levels from baseline after 12 weeks of treatment. 
Non-HDL-C levels were reduced by 39% (P , 0.001) in 
the pitavastatin group and by 40.3% (P , 0.001) in the 
atorvastatin group. The percent reduction in non-HDL-C 
levels showed a statistically significant positive correlation 
with waist circumference and body mass index (BMI) only 
in the atorvastatin group (r = 0.33, P = 0.034 and r = 0.279, 
P = 0.022, respectively); no significant correlation for these 
parameters was found in the pitavastatin group. There were 
no statistically significant between-group differences in the 
percent changes in LDL-C, TG, HDL-C, and non-HDL-C. 
HDL-C increased significantly only in the pitavastatin group 
(3.2%, P = 0.033). The percent changes in LDL-C were 
42.6% (P , 0.001) and 44.1% (P , 0.001) in the pitavasta-
tin and atorvastatin groups, respectively. Subgroup analysis 
was also conducted in patients with metabolic syndrome. 
In this subanalysis, LDL-C reduction in the pitavastatin 
group showed a tendency to be significantly superior to 
that in the atorvastatin group (P = 0.050), and the percent 
change in TG (–25.2%, P , 0.001) as well as HDL-C 
(6.7%, P = 0.019) was statistically significant only in the 
pitavastatin group. Both treatments were well tolerated, 
but aspartate aminotransferase, alanine aminotransferase, 
and gamma-glutamyl transpeptidase became elevated in 
atorvastatin group.
PiAT study
The PIAT study was conducted to examine the effects of 
pitavastatin and atorvastatin on HDL-C levels in patients with 
elevated LDL-C and glucose intolerance.39 In this study, the 
primary endpoint was the percent change in HDL-C levels 
following treatment with 2 mg/day pitavastatin or 10 mg/day 
atorvastatin for 52 weeks (described further on in this review 
with regard to the HDL-C-elevating effect of pitavastatin). 
The subjects were 173 hypercholesterolemic patients with 
glucose intolerance or Type 2 diabetes mellitus who had 
LDL-C levels $ 140 mg/dL, HDL-C levels , 80 mg/dL, 
and TG levels , 500 mg/dL. The LDL-C reductions in the 
pitavastatin group and atorvastatin group after treatment for 
eight weeks (a treatment duration similar to that used in other 
studies) were 36.8% and 37.9%, respectively (P = 0.61), 
which were reported by Sasaki in the XVI International 
Symposium on Drugs Affecting Lipid Metabolism in New 
York, USA in 2007. No significant differences between 
in CHIBA (Collaborative Study on Hypercholesterolemia 
Drug Intervention and their Benefits for Atherosclerosis 
Prevention)43 conducted in Japan, and 44.4% using 2 mg/
day pitavastatin in a Korean study that used atorvastatin as a 
control,44 respectively. The LDL-C-lowering effects of 2 mg/
day pitavastatin in other studies conducted in Japan, Korea, 
and Europe39,43–49 ranged from 36.8% to 39%. The LDL-C-
lowering effects of 4 mg/day pitavastatin ranged from 44.0% 
to 44.6% in the Phase III studies conducted in Europe.47–49 
The LDL-C-lowering effects of 1 mg/day pitavastatin was 
31.4% in a Phase III study conducted in Europe.49 Randomized 
controlled studies that compared the LDL-C-lowering effect 
of 4 mg/day pitavastatin with that of other statins in patients 
with primary hypercholesterolemia or combined dyslipidemia 
have not been reported in Japan, Korea, or Thailand. However, 
two studies conducted in patients with ACS in Japan showed 
that LDL-C levels were reduced by 36% from 131 mg/dL at 
baseline and by 31% from 115 mg/dL at baseline.40,41
The LDL-C-lowering effects following the administra-
tion of 2 mg/day and 4 mg/day pitavastatin are thought to be 
comparable with those observed following the administration 
of 10 mg/day and 20 mg/day atorvastatin and 20 mg/day 
and 40 mg/day simvastatin. The safety and tolerability of 
pitavastatin were similar to those of controls in the random-
ized controlled studies. Each study is outlined below.
Phase iii Japanese study  
of pitavastatin versus pravastatin
The effects of 2 mg/day pitavastatin were compared with the 
effects of a regular dose of 10 mg/day pravastatin, which was 
the most commonly used statin in Japan at the time of this 
study.45 In 225 patients with total cholesterol (TC) levels $ 
220 mg/dL and triglyceride (TG) levels , 400 mg/dL, the 
LDL-C-lowering effect of pitavastatin after administration 
for 12 weeks was significantly better than that of pravasta-
tin (37.6%, 95% confidence interval [CI] 35.3–39.9 versus 
18.4%, 95% CI 16.1–20.7, respectively; the 95% CI of the 
difference was 11.8–16.5). In patients with baseline TG 
levels $ 150 mg/dL, the TG-lowering-effect was 23.3% 
(95% CI 13.7–32.9) and 20.2% (95% CI 12.0–28.4) in the 
pitavastatin group and the pravastatin group, respectively. 
HDL-C levels increased by 8.9% (95% CI 6.4–11.4) and 
9.8% (95% CI 6.4–11.4), respectively.
CHiBA study
Since pitavastatin was launched in Japan in 2003, several 
investigator-initiated randomized comparative studies 
have been conducted, including the Chiba trial.43 In this Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the two groups were observed with regard to worsening of 
  glucose metabolism or incidence of adverse events.
Comparative study of pitavastatin  
and simvastatin in Korea
In this study, 103 hypercholesterolemic patients with LDL-C 
levels $ 130 mg/dL and TG levels , 600 mg/dL received 
2 mg/day pitavastatin or 20 mg/day simvastatin for eight 
weeks.46 The LDL-C reduction was 38.2% in the pitavas-
tatin group and 39.4% in the simvastatin group; there was 
no significant difference between the groups (P = 0.648) for 
percent changes in TC, TG, and HDL-C, or the proportion of 
patients attaining the LDL-C treatment goals recommended 
in the National Cholesterol Education Program (NCEP)-
Adult Treatment Panel (ATP) III guidelines. The incidence 
of adverse events was not significantly different between 
the groups (25.0% in the pitavastatin group and 37.3% in 
the simvastatin group, P = 0.179). However, the incidence 
of adverse events that had an undeniable causal relationship 
with the study drug was 15.4% in the pitavastatin group and 
37.3% in the simvastatin group, indicating a significant dif-
ference between the groups (P = 0.015).
Comparative study of pitavastatin  
and atorvastatin in Korea
In this study, 268 hypercholesterolemic patients with LDL-C 
levels $ 130 mg/dL and TG levels , 400 mg/dL received 
2 mg/day pitavastatin or 10 mg/day atorvastatin for four 
weeks, followed another four-week treatment with uptitra-
tion when a patient did not achieve the NCEP-ATP III goal.44 
Thus, the study drugs were administered for a total of eight 
weeks. The LDL-C reduction was 44.4% in the pitavastatin 
group and 43.2% in the atorvastatin group after four weeks, 
indicating no significant difference between the groups 
(P = 0.41). Tolerability was good in both groups. The inci-
dence of adverse events was 19.1% in the pitavastatin group 
and 25.0% in the atorvastatin group. Increased creatine kinase 
levels equal to or higher than 10 times the upper limit of the 
normal range, with muscle symptoms, did not occur.
Comparative study of pitavastatin  
and atorvastatin in Thailand
A study conducted in Thailand compared the LDL-C 
reduction using 1 mg/day pitavastatin with that of 10 mg/
day atorvastatin.42 In a total of 100 patients with hyper-
cholesterolemia, the LDL-C reduction after treatment 
(P , 0.001) in 74% and 84% of subjects in the pitavastatin 
and atorvastatin groups, respectively, achieved the LDL-C 
goal recommended in the NCEP-ATP III guidelines, with 
no significant difference between the groups (P = 0.220). 
Tolerability was good in both groups. Elevation of alanine 
transaminase levels equal to or higher than three times the 
upper limit of normal or elevation of creatine kinase levels 
equal to or higher than 10 times the upper limit of normal did 
not occur. The monthly cost per percent LDL-C reduction 
by pitavastatin 1 mg/day was less than that for atorvastatin 
10 mg/day in Thailand.
Comparative study of pitavastatin  
and atorvastatin in europe
This study was conducted in 821 patients with hypercholes-
terolemia or combined dyslipidemia whose LDL-C levels 
were between 160 and 220 mg/dL and whose TG levels 
were #400 mg/dL.48 The study aimed to compare the LDL-C 
reductions following treatment with pitavastatin for 12 weeks 
with those after atorvastatin treatment for the same duration 
(pitavastatin 2 mg/day versus atorvastatin 10 mg/day and 
pitavastatin 4 mg/day versus atorvastatin 20 mg/day). The 
LDL-C reductions were 37.9% (pitavastatin 2 mg/day), 37.8% 
(atorvastatin 10 mg/day), 44.6% (pitavastatin 4 mg/day), and 
43.5% (atorvastatin 20 mg/day), indicating no significant 
differences between the pitavastatin and atorvastatin groups 
(P = 0.93 between the lower dose groups and 0.57 between 
the higher dose groups, respectively). There were no signifi-
cant between-group differences in the percent changes in TC, 
TG, HDL-C, and non-HDL-C or the rates of achievement of 
the LDL-C goal. Tolerability was good in both groups. The 
incidence of adverse events was 19.0% (pitavastatin 2 mg/
day), 16.7% (atorvastatin 10 mg/day), 16.7% (pitavastatin 
4 mg/day), and 22.3% (atorvastatin 20 mg/day).
Comparative study of pitavastatin  
and simvastatin in europe
This study was conducted in 857 patients with hyper-
cholesterolemia or combined dyslipidemia whose LDL-C 
levels were between 160 and 220 mg/dL and whose TG 
levels were #400 mg/dL.47 The study compared the 
LDL-C reductions following treatment with pitavastatin 
for 12 weeks with those after treatment with simvastatin 
for the same duration (pitavastatin 2 mg/day versus sim-
vastatin 20 mg/day and pitavastatin 4 mg/day versus sim-
vastatin 40 mg/day). The LDL-C reductions were 39.0% 
(pitavastatin 2 mg/day), 35.0% (simvastatin 20 mg/day), 
44.0% (pitavastatin 4 mg/day), and 42.8% (simvastatin 
40 mg/day). The LDL-C reduction following treatment 
with 2 mg/day pitavastatin was significantly better than that Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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after treatment with 20 mg/day simvastatin (P = 0.014). 
The percent changes in TC and non-HDL-C levels and 
the rate of achievement of the LDL-C goal recommended 
in the European Atherosclerosis Society guidelines in 
the pitavastatin 2 mg/day group were similarly superior 
to those in the simvastatin 20 mg/day group (P = 0.041, 
0.021, and 0.049, respectively). The percent changes in TG 
and HDL-C and the rate of achievement of the LDL-C goal 
recommended in the NCEP-ATP III guidelines did not dif-
fer significantly between the treatment groups. Tolerability 
was good in both groups. The incidence of adverse events 
was 35.4% (pitavastatin 2 mg/day), 33.6% (simvastatin 
20 mg/day), 32.2% (pitavastatin 4 mg/day), and 27.3% 
(simvastatin 40 mg/day).
Comparative study of pitavastatin  
and pravastatin in europe
This study was conducted in elderly patients with hypercho-
lesterolemia or combined dyslipidemia whose LDL-C levels 
were between 130 and 220 mg/dL and whose TG levels were 
#400 mg/dL. The study compared LDL-C reductions fol-
lowing administration of pitavastatin for 12 weeks with those 
following administration of pravastatin for the same duration 
(pitavastatin 1 mg/day versus pravastatin 10 mg/day, pitavas-
tatin 2 mg/day versus pravastatin 20 mg/day, and pitavastatin 
4 mg/day versus pravastatin 40 mg/day).49 The LDL-C reduc-
tions were 31.4% (pitavastatin 1 mg/day), 22.4% (pravas-
tatin 10 mg/day), 39.0% (pitavastatin 2 mg/day), 28.8% 
(pravastatin 20 mg/day), 44.3% (pitavastatin 4 mg/day), 
and 34.0% (pravastatin 40 mg/day). The LDL-C reduction 
following pitavastatin treatment was significantly superior 
to that following pravastatin treatment at each dose com-
parison (P , 0.001). Adverse events were similar for the 
pitavastatin and pravastatin groups. Tolerability was good 
in both groups.
JAPAN-ACS study
JAPAN-ACS (Japanese Assessment of Pitavastatin and 
Atorvastatin in ACS) was conducted in 252 patients 
with ACS who had successfully undergone intravascular 
ultrasound-guided percutaneous coronary intervention.40 In 
this study, the percent change in coronary plaque volume 
after treatment with 4 mg/day pitavastatin for 8–12 months 
was compared with that after 20 mg/day atorvastatin for 
the same duration. This study indicated the regressive 
effect of aggressive lipid-lowering therapy on coronary 
plaque volume in patients with ACS who had undergone 
intravascular ultrasound-guided percutaneous coronary 
intervention. The plaque regressive effect of pitavastatin 
was equivalent to that of atorvastatin. The LDL-C reduction 
was equivalent in the pitavastatin and atorvastatin groups 
(36.2% and 35.8%, respectively, P = 0.9). The LDL-C 
reductions were relatively smaller than those seen in the 
other studies because the LDL-C levels were low at baseline 
(130.9 mg/dL in the pitavastatin group and 133.8 mg/dL in 
the atorvastatin group). Unlike in other placebo-controlled 
studies, the percent change in LDL-C was not correlated 
with the percent change in plaque volume in the JAPAN-
ACS study. No significant differences were found in the 
incidence rate of cardiovascular or adverse events between 
the treatment groups.
Pitavastatin versus atorvastatin using  
virtual histology intravascular ultrasound
A study conducted in 160 patients with ACS who under-
went percutaneous coronary intervention reported the early 
effects of 2–3 weeks’ treatment with 2 mg/day pitavastatin 
and 10 mg/day atorvastatin on the components of coro-
nary plaques.41 After treatment, the plaque volume index 
and fibrofatty plaque (a component of coronary plaques) 
volume index decreased significantly in the pitavastatin 
group (P , 0.05). The mean LDL-C level at baseline was 
114.7 mg/dL in the pitavastatin group and 122.0 mg/dL in 
the atorvastatin group; both levels were lower than those in 
the JAPAN-ACS study. The LDL-C reduction was 31.0% 
in the pitavastatin group (P , 0.001) and 27.9% in the ator-
vastatin group (P , 0.001). The percent change in plaque 
volume index showed a mild positive correlation with the 
percent change in LDL-C in the pitavastatin group. In a 
subgroup of patients in the pitavastatin group with a dense 
calcium plaque ratio less than 10%, the percent change in 
fibrofatty volume index and the percent change in LDL-C 
correlated positively.
HDL-C-elevating effect of pitavastatin
HDL-C elevation following treatment with pitavastatin for 
4–12 weeks ranged from 3.2% to 8.9% in a population with 
baseline HDL-C levels between 48.5 and 58.5 mg/dL in 
the randomized, active-controlled comparative study (see 
Table 1). The PIAT study39 compared treatment for 52 weeks 
with 2 mg/day pitavastatin and 10 mg/day atorvastatin. 
Because pitavastatin has an LDL-C-lowering effect similar 
to that of atorvastatin but is expected to have a superior 
HDL-  C-elevating effect, PIAT also assessed the effects of Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Figure 1 Time course of high-density lipoprotein cholesterol levels in long-term clinical studies of pitavastatin.
Note: Data are expressed as mean ± standard deviation. Reference 52 is subanalysis for patients whose baseline high-density lipoprotein cholesterol was ,40 mg/dL.
pitavastatin and atorvastatin on the HDL-C levels of patients 
with elevated LDL-C and glucose intolerance.39 Patients 
with glucose intolerance or Type 2 diabetes mellitus were 
chosen because HDL-C levels, in addition to LDL-C levels, 
play a particularly important role in cardiovascular risk in 
these patients.
Pitavastatin was significantly superior to atorvastatin 
with regard to the increase in HDL-C levels after 52 weeks 
(8.8% versus 3.6%, respectively, P = 0.034). This result 
was sustained throughout the 52 weeks of treatment. The 
percent change in the level of Apoprotein A-1, a major 
protein component of HDL-C, was significantly higher in 
the pitavastatin group than in the atorvastatin group after 
52 weeks (5.2% versus 1.1%, respectively, P = 0.031). 
Pitavastatin had a persistent HDL-C-elevating effect. 
Moreover, various nonrandomized studies that examined 
the effects of long-term administration of pitavastatin 
reported a sustained increase in HDL-C levels with 
pitavastatin treatment (see Figure 1).39,50–53 In addition 
to the potent LDL-C-lowering effect of pitavastatin, its 
long-term HDL-C-elevating effect is expected to provide 
some long-term benefits, but further confirmation of these 
results is warranted.
Conclusion
Pitavastatin has a potent serum LDL-C-lowering effect, 
even at low doses of 1–4 mg/day. Pitavastatin also affects 
regression of coronary plaques, as observed in intravascular 
ultrasound-guided percutaneous coronary intervention stud-
ies. Moreover, the persistent long-term HDL-C elevation 
observed in patients treated with pitavastatin is worthy of fur-
ther attention. The reported improvements in the lipid profile 
are consistent between the studies conducted in Japan, Korea, 
Thailand, and Europe. Pitavastatin has a lower propensity for 
drug–drug interactions via CYP, can exert a potent LDL-C-
lowering effect at relatively low doses, and has a favorable 
effect on coronary plaques. Therefore, it is expected that, as 
clinical experience of pitavastatin   accumulates worldwide, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
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this statin will establish its position as a useful drug for 
preventing and treating cardiovascular disease.
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